报道

订阅

MedSci主页 / 所有栏目 / 报道

喜鹊医药研发的糖尿病肾病创新药硝酮嗪进入临床2期

2019-11-30 不详 网络

喜鹊医药糖尿病肾病
关注

广州喜鹊医药有限公司（以下简称“喜鹊医药”）创新药物硝酮嗪治疗糖尿病肾病II期临床研究于2019年11月26日在北京同仁医院顺利启动。启动会由创新药物硝酮嗪治疗糖尿病肾病II期临床研究组组长, 北京同仁医院内分泌科主任, 北京市糖尿病研究所所长，北京学者杨金奎教授主持。该临床II期研究的主要目的是评价硝酮嗪在糖尿病肾病患者中的有效性和安全性。 杨金奎教授表示，“虽然近年来糖尿病肾病的

广州喜鹊医药有限公司（以下简称“喜鹊医药”）创新药物硝酮嗪治疗糖尿病肾病II期临床研究于2019年11月26日在北京同仁医院顺利启动。启动会由创新药物硝酮嗪治疗糖尿病肾病II期临床研究组组长, 北京同仁医院内分泌科主任, 北京市糖尿病研究所所长，北京学者杨金奎教授主持。该临床II期研究的主要目的是评价硝酮嗪在糖尿病肾病患者中的有效性和安全性。

杨金奎教授表示，“虽然近年来糖尿病肾病的治疗取得了很大进展，但现有药物还远不能满足临床需求。硝酮嗪设计巧妙，在中药川芎嗪的基础上进行结构改造，作用机理新颖，是对中药的创新。硝酮嗪治疗糖尿病肾病的II期临床研究要求严格，期望能获得好的临床结果” 。

喜鹊医药总经理王玉强博士表示，“由著名学者杨金奎教授领衔、国内多家医院参加的高水平研究团队是整个II期临床研究的强力保障，将能确保研究质量高，推进速度快。期待喜鹊医药自主创新的糖尿病肾病治疗药物硝酮嗪能够通过高水平的临床研究，为患者的健康报喜”。

 

关于硝酮嗪

硝酮嗪是喜鹊医药自主创新的I类化学新药，是对中药川芎嗪进行结构改造获得的药物分子，具有独特的作用机理。糖尿病肾病动物模型研究发现，硝酮嗪疗效显著，能够明显降低蛋白尿、有效保护肾脏组织和胰岛β细胞。硝酮嗪治疗急性缺血性脑卒中和糖尿病肾病项目正在进行II期临床研究。

关于糖尿病肾病

糖尿病肾病(Diabetic Kidney Disease, DKD)是糖尿病引起的严重和危害性最大的并发症。中国是糖尿病第一大国，患者人数超过一亿，其中大约1/3的患者会并发糖尿病肾病。糖尿病患者一旦出现蛋白尿，大约有50%最终会发展为尿毒症。虽然糖尿病肾病对人类健康具有极大威胁，现代医学对糖尿病肾病的研究和治疗尚未有突破性进展，临床急需疗效显著作用机理独特的创新药物。

关于喜鹊医药

喜鹊医药2011年成立于广州，是一家临床阶段的First-in-Class “全球新” 药物研究开发公司，专注于市场潜力大但临床需求尚未得到有效满足的心脑血管和线粒体疾病创新治疗药物的研究开发。依托其独特的新药创制平台，喜鹊医药在脑卒中、糖尿病肾病、帕金森病、痴呆症、青光眼和心肌缺血等领域进行了深度布局；同时，喜鹊医药也在积极布局针对肌萎缩性侧索硬化症和肺动脉高血压等罕见病治疗创新药物的开发。更多信息可访问，http://magpiepharma.com。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707171, encodeId=d26f1e07171d2, content=<a href='/topic/show?id=5e8840161cb' target=_blank style='color:#2F92EE;'>#喜鹊医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40161, encryptionId=5e8840161cb, topicName=喜鹊医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d7731366331, createdName=肉我只吃一口, createdTime=Wed Sep 16 23:30:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993979, encodeId=237019939e995, content=<a href='/topic/show?id=864a353653f' target=_blank style='color:#2F92EE;'>#医药研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35365, encryptionId=864a353653f, topicName=医药研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Jan 30 16:30:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285826, encodeId=357d128582646, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300332, encodeId=ffe7130033281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409949, encodeId=84041409949cb, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042847, encodeId=5ef2104284efa, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 30 23:30:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2020-09-16 肉我只吃一口

    #喜鹊医药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1707171, encodeId=d26f1e07171d2, content=<a href='/topic/show?id=5e8840161cb' target=_blank style='color:#2F92EE;'>#喜鹊医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40161, encryptionId=5e8840161cb, topicName=喜鹊医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d7731366331, createdName=肉我只吃一口, createdTime=Wed Sep 16 23:30:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993979, encodeId=237019939e995, content=<a href='/topic/show?id=864a353653f' target=_blank style='color:#2F92EE;'>#医药研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35365, encryptionId=864a353653f, topicName=医药研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Jan 30 16:30:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285826, encodeId=357d128582646, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300332, encodeId=ffe7130033281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409949, encodeId=84041409949cb, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042847, encodeId=5ef2104284efa, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 30 23:30:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2020-01-30 lishiwen

    #医药研发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1707171, encodeId=d26f1e07171d2, content=<a href='/topic/show?id=5e8840161cb' target=_blank style='color:#2F92EE;'>#喜鹊医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40161, encryptionId=5e8840161cb, topicName=喜鹊医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d7731366331, createdName=肉我只吃一口, createdTime=Wed Sep 16 23:30:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993979, encodeId=237019939e995, content=<a href='/topic/show?id=864a353653f' target=_blank style='color:#2F92EE;'>#医药研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35365, encryptionId=864a353653f, topicName=医药研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Jan 30 16:30:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285826, encodeId=357d128582646, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300332, encodeId=ffe7130033281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409949, encodeId=84041409949cb, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042847, encodeId=5ef2104284efa, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 30 23:30:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2019-12-02 一叶知秋

    #创新#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1707171, encodeId=d26f1e07171d2, content=<a href='/topic/show?id=5e8840161cb' target=_blank style='color:#2F92EE;'>#喜鹊医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40161, encryptionId=5e8840161cb, topicName=喜鹊医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d7731366331, createdName=肉我只吃一口, createdTime=Wed Sep 16 23:30:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993979, encodeId=237019939e995, content=<a href='/topic/show?id=864a353653f' target=_blank style='color:#2F92EE;'>#医药研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35365, encryptionId=864a353653f, topicName=医药研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Jan 30 16:30:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285826, encodeId=357d128582646, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300332, encodeId=ffe7130033281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409949, encodeId=84041409949cb, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042847, encodeId=5ef2104284efa, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 30 23:30:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2019-12-02 lqvr

    #研发#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1707171, encodeId=d26f1e07171d2, content=<a href='/topic/show?id=5e8840161cb' target=_blank style='color:#2F92EE;'>#喜鹊医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40161, encryptionId=5e8840161cb, topicName=喜鹊医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d7731366331, createdName=肉我只吃一口, createdTime=Wed Sep 16 23:30:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993979, encodeId=237019939e995, content=<a href='/topic/show?id=864a353653f' target=_blank style='color:#2F92EE;'>#医药研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35365, encryptionId=864a353653f, topicName=医药研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Jan 30 16:30:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285826, encodeId=357d128582646, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300332, encodeId=ffe7130033281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409949, encodeId=84041409949cb, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042847, encodeId=5ef2104284efa, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 30 23:30:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2019-12-02 cathymary

    #医药#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1707171, encodeId=d26f1e07171d2, content=<a href='/topic/show?id=5e8840161cb' target=_blank style='color:#2F92EE;'>#喜鹊医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40161, encryptionId=5e8840161cb, topicName=喜鹊医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d7731366331, createdName=肉我只吃一口, createdTime=Wed Sep 16 23:30:00 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1993979, encodeId=237019939e995, content=<a href='/topic/show?id=864a353653f' target=_blank style='color:#2F92EE;'>#医药研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35365, encryptionId=864a353653f, topicName=医药研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Jan 30 16:30:00 CST 2020, time=2020-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285826, encodeId=357d128582646, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300332, encodeId=ffe7130033281, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409949, encodeId=84041409949cb, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Mon Dec 02 11:30:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042847, encodeId=5ef2104284efa, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Nov 30 23:30:00 CST 2019, time=2019-11-30, status=1, ipAttribution=)]
    2019-11-30 misszhang

    谢谢MedSci提供最新的资讯

    0